Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis - ScienceDirect
Activatory and Inhibitory Fcγ Receptors Augment Rituximab-mediated Internalization of CD20 Independent of Signaling via the Cytoplasmic Domain* - Journal of Biological Chemistry
Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies | Inflammation and Regeneration | Full Text
Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis - The Journal of Allergy and Clinical Immunology: In Practice
Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome | The Journal of Rheumatology
Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity - Multiple Sclerosis and Related Disorders
Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease - European Journal of Internal Medicine
Current perspective on rituximab in rheumatic diseases | DDDT
Hypersialylation characterizes CLL cells resistant to rituximab (RTX)... | Download Scientific Diagram
Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology | American Society of Nephrology
Rituximab Prolongs the Time to Relapse in Patients with Immune Thrombotic Thrombocytopenic Purpura: Analysis of Off-Label Use in Japan - ISTH Congress Abstracts
How does ocrelizumab differ from rituximab? - Quora
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo | Leukemia
Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study - ACR Meeting Abstracts
Non-Hodgkin Lymphoma | Encyclopedia MDPI
Rituximab (RTX)-induces in vitro complement-dependent cytotoxicity... | Download Scientific Diagram
Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text
In vitro and in vivo treatment with rituximab (RTX) leads to CD20KO... | Download Scientific Diagram
Rituximab (RTX) stimulation induces SHP-1 recruitment to CD16 z chain.... | Download Scientific Diagram
Increase in the density of CD20 improves the efficacy of rituximab (... | Download Scientific Diagram
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients - ACR Meeting Abstracts
specificity for rituximab (rtx) and infliximab (ifx) peptides of the... | Download Scientific Diagram
Internalization of rituximab (RTX) to a highly variable extent,... | Download Scientific Diagram
Efficacy and safety of different dosages of rituximab for refractory
